

Telisotuzumab vedotin

Cat. No.:	HY-141601
CAS No.:	1714088-51-3
Target:	Antibody-Drug Conjugates (ADCs); c-Met/HGFR
Pathway:	Antibody-drug Conjugate/ADC Related; Protein Tyrosine Kinase/RTK
Storage:	-80°C, protect from light

Telisotuzumab vedotin

BIOLOGICAL ACTIVITY

Description

Telisotuzumab vedotin (ABBV-399) is an antibody-drug conjugate (ADCs) targeting c-Met. Telisotuzumab vedotin consists of Monomethyl Auristatin E (MMAE), Telisotuzumab antibody and a cleavable mc-val-cit-PABC type linker. Telisotuzumab vedotin can be used in cancer research^[1].

REFERENCES

[1]. Strickler JH, et al. First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors. *J Clin Oncol*. 2018 Nov 20;36(33):3298-3306.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA